van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. The Lancet. 2021;397(10272):410–27.

Article  Google Scholar 

Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10(9):94.

Article  PubMed  PubMed Central  Google Scholar 

Sonneveld P, Goldschmidt H, Rosinol L, Blade J, Lahuerta JJ, Cavo M, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol. 2013;31(26):3279–87.

Article  CAS  PubMed  Google Scholar 

Jackson GH, Pawlyn C, Cairns DA, Striha A, Collett C, Waterhouse A, et al. Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, phase III trial. Br J Haematol. 2021;192(5):853–68.

Article  CAS  PubMed  Google Scholar 

Chong LL, Soon YY, Soekojo CY, Ooi M, Chng WJ, de Mel S. Daratumumab-based induction therapy for multiple myeloma: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021;159.

Holstein SA, McCarthy PL. Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience. Drugs. 2017;77(5):505–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kumar SK, Rajkumar SV. The multiple myelomas — current concepts in cytogenetic classification and therapy. Nat Rev Clin Oncol. 2018;15(7):409–21.

Article  CAS  PubMed  Google Scholar 

Egan P, Drain S, Conway C, Bjourson AJ, Alexander HD. Towards stratified medicine in plasma cell myeloma. Int J Mol Sci. 2016;17(10):1760.

Article  PubMed  PubMed Central  Google Scholar 

Lang N, Crump M. PET-adapted approaches to primary therapy for advanced Hodgkin lymphoma. Ther Adv Hematol. 2020;11:2040620720914490.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Voorhees P. On the need for phase III studies of risk-adapted therapy in multiple myeloma. Biol Blood Marrow Transplant. 2017;23(2):181–2.

Article  PubMed  Google Scholar 

Lahuerta JJ, Mateos MV, Martinez-Lopez J, Rosinol L, Sureda A, de la Rubia J, et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol. 2008;26(35):5775–82.

Article  PubMed  Google Scholar 

van de Velde H, Londhe A, Ataman O, Johns HL, Hill S, Landers E, et al. Association between complete response and outcomes in transplant-eligible myeloma patients in the era of novel agents. Eur J Haematol. 2017;98(3):269–79.

Article  PubMed  Google Scholar 

Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R, et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood. 2011;117(11):3025–31.

Article  CAS  PubMed  Google Scholar 

Kaddoura M, Binder M, Dingli D, Buadi FK, Lacy MQ, Gertz MA, et al. Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome. Am J Hematol. 2022;97(3):267–73.

Article  CAS  PubMed  Google Scholar 

Vij R, Kumar S, Zhang MJ, Zhong X, Huang J, Dispenzieri A, et al. Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2015;21(2):335–41.

Article  PubMed  Google Scholar 

Ross DM, To LB, Horvath N. Assessment of early paraprotein response to vincristine-doxorubicin-dexamethasone chemotherapy may help guide therapy in multiple myeloma. Intern Med J. 2004;34(9–10):576–8.

Article  CAS  PubMed  Google Scholar 

Schaar CG, Kluin-Nelemans JC, le Cessie S, Franck PF, te Marvelde MC, Wijermans PW. Early response to therapy and survival in multiple myeloma. Br J Haematol. 2004;125(2):162–6.

Article  CAS  PubMed  Google Scholar 

Tandon N, Sidana S, Rajkumar SV, Gertz MA, Buadi FK, Lacy MQ, et al. Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma. Blood Adv. 2019;3(5):744–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yan Y, Mao X, Liu J, Fan H, Du C, Li Z, et al. The impact of response kinetics for multiple myeloma in the era of novel agents. Blood Adv. 2019;3(19):2895–904.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, et al. Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. The lancet Haematology. 2019;6(12):e616–29.

Article  PubMed  PubMed Central  Google Scholar 

Niesvizky R, Mark TM, Ward M, Jayabalan DS, Pearse RN, Manco M, et al. Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization. Clin Cancer Res. 2013;19(6):1534–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet (london, england). 2017;389(10068):519–27.

Article  CAS  PubMed  Google Scholar 

Shah GL, Weltz J, Zhou Q, Devlin SM, Landau H, Chung DJ, et al. A response adapted approach to induction treatment in patients with multiple myeloma undergoing autologous stem cell transplantation. Biol Blood Marrow Transplant. 2016;22(3):S40–1.

Article  Google Scholar 

Yoo KH, Yoon DH, Kang HJ, Lee WS, Kim K, Kim JS, et al. Multicenter, phase II study of response-adapted lenalidomide-based therapy for transplant-ineligible patients with newly diagnosed multiple myeloma without high-risk features. Curr Probl Cancer. 2022;46(1):100788.

Article  PubMed  Google Scholar 

Narkhede M, Valent J, Cummings C, Glass K, Hastings D, Faiman B, et al. Results of an upfront myeloma carepath pilot with response-adapted therapy. Blood. 2014;124(21):2620.

Article  Google Scholar 

Charalampous C, Kourelis T. Minimal residual disease assessment in multiple myeloma patients: minimal disease with maximal implications. Front Oncol. 2022;11.

Kumar S, Paiva B, Anderson K, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–46.

Article  PubMed  Google Scholar 

Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–46.

Article  PubMed  Google Scholar 

Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132(23):2456–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Munshi NC, Avet-Loiseau H, Rawstron AC, Owen RG, Child JA, Thakurta A, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017;3(1):28–35.

Article  PubMed  PubMed Central  Google Scholar 

Paiva B, Puig N, Cedena MT, Rosinol L, Cordon L, Vidriales MB, et al. Measurable residual disease by next-generation flow cytometry in multiple myeloma. J Clin Oncol. 2020;38(8):784–92.

Article  CAS  PubMed  Google Scholar 

Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol. 2022;40(25):2901–12.

Article  CAS  PubMed  Google Scholar 

Chen Y, Gopalakrishnan SK, Ooi M, Sultana R, Lim LH, Grigoropoulos N, et al. A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1). Blood Cancer J. 2021;11(9):150.

Article  PubMed  PubMed Central  Google Scholar 

Korde N, Mastey D, Tavitian E, Mailankody S, Lesokhin A, Hassoun H, et al. Tailored treatment to MRD response: a phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m(2)) in combination with lenalidomide and dexamethasone. Am J Hematol. 2021;96(6):E193–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hahn TE, Wallace PK, Fraser R, Fei M, Tario JD, Howard A, et al. Minimal Residual Disease (MRD) Assessment before and after autologous hematopoietic cell transplantation (AutoHCT) and maintenance for multiple myeloma (MM): results of the Prognostic Immunophenotyping for Myeloma Response (PRIMeR) study. Biol Blood Marrow Transplant. 2019;25(3):S4–6.

Article  Google Scholar 

Junghans RP, Anderson CL. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci. 1996;93(11):5512–6.